Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.
Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.
March 2011 Describes a study revealing that HIV-infected prisoners in Texas often experience an interruption in treatment following their release and that assistance in filling out paperwork can reduce these interruptions.
October 2010 Recognizes four scientists for the 2009 Avant-Garde Award for HIV research, an award intended to stimulate groundbreaking research for the prevention and treatment of HIV/AIDS in drug abusers.
December 2009 Reports finding from a study showing that access to antiretroviral therapies, HAART in particular, can improve the health of HIV-infected patients who have a history of injection drug use.
November 2009 Discusses the work of NIDA’s Division of Epidemiology, Services and Prevention Research, organized to track drug use and provide empirically based information for researchers and service providers.